Immunogenicity and safety of the adjuvanted recombinant zoster vaccine in patients with solid tumors, vaccinated before or during chemotherapy: A randomized trial-Reference-Cited by-同舟云学术

Immunogenicity and safety of the adjuvanted recombinant zoster vaccine in patients with solid tumors, vaccinated before or during chemotherapy: A randomized trial

Published:2019-02 Issue:8 Volume:125 Page:1301-1312
ISSN:0008-543X
Container-title:Cancer
language:en
Short-container-title:Cancer

Author:

Vink Peter¹,Delgado Mingorance Ignacio²,Maximiano Alonso Constanza³,Rubio‐Viqueira Belen⁴,Jung Kyung Hae⁵,Rodriguez Moreno Juan Francisco⁶,Grande Enrique⁷,Marrupe Gonzalez David⁸,Lowndes Sarah⁹,Puente Javier¹⁰,Kristeleit Hartmut¹¹,Farrugia David¹²,McNeil Shelly A.¹³,Campora Laura¹⁴,Di Paolo Emmanuel¹⁵,El Idrissi Mohamed¹⁵,Godeaux Olivier¹⁶,López‐Fauqued Marta¹⁴,Salaun Bruno¹⁵,Heineman Thomas C.¹⁷,Oostvogels Lidia¹⁴,

Affiliation:

1. GSK Rockville Maryland

2. Hospital Infanta Cristina Badajoz Spain

3. Hospital Universitario Puerta de Hierro Majadahonda Madrid Spain

4. Hospital Universitario Quiron Madrid Pozuelo de Alarcón Spain

5. Asan Medical Center University of Ulsan College of Medicine Seoul South Korea

6. Centro Integral Oncologico Clara Campal Madrid Spain

7. Ramon y Cajal University Hospital Madrid Spain

8. Hospital Universitario de Mostoles Madrid Spain

9. Great Western Hospital Swindon United Kingdom

10. Medical Oncology Department Hospital Clínico San Carlos Madrid Spain

11. Queen Elizabeth Hospital Woolwich United Kingdom